Knockout of Purinergic P2Y6 Receptor Fails to Improve Liver Injury and Inflammation in Non-Alcoholic Steatohepatitis

被引:3
|
作者
Nishiyama, Kazuhiro [1 ]
Ariyoshi, Kohei [1 ]
Nishimura, Akiyuki [2 ,3 ]
Kato, Yuri [1 ]
Mi, Xinya [1 ]
Kurose, Hitoshi [1 ]
Kim, Sang Geon [4 ]
Nishida, Motohiro [1 ,2 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan
[2] Natl Inst Physiol Sci NIPS, Natl Inst Nat Sci, Okazaki 4448787, Japan
[3] Natl Inst Nat Sci, Exploratory Res Ctr Life & Living Syst ExCELLS, Okazaki 4448787, Japan
[4] Dongguk Univ Seoul, Coll Pharm, Goyang Si 10326, Gyeonggi Do, South Korea
基金
新加坡国家研究基金会;
关键词
purinergic P2Y(6) receptor; nonalcoholic steatohepatitis; inflammation; INSULIN-RESISTANCE; OXIDATIVE STRESS; MICE; EXPRESSION; ACTIVATION; METHIONINE; FIBROSIS; CHOLINE; INHIBITION; AUTOPHAGY;
D O I
10.3390/ijms24043800
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nonalcoholic steatohepatitis (NASH) is a disease that progresses from nonalcoholic fatty liver (NAFL) and which is characterized by inflammation and fibrosis. The purinergic P2Y(6) receptor (P2Y(6)R) is a pro-inflammatory G(q)/G(12) family protein-coupled receptor and reportedly contributes to intestinal inflammation and cardiovascular fibrosis, but its role in liver pathogenesis is unknown. Human genomics data analysis revealed that the liver P2Y(6)R mRNA expression level is increased during the progression from NAFL to NASH, which positively correlates with inductions of C-C motif chemokine 2 (CCL2) and collagen type I alpha 1 chain (Col1a1) mRNAs. Therefore, we examined the impact of P2Y(6)R functional deficiency in mice crossed with a NASH model using a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD). Feeding CDAHFD for 6 weeks markedly increased P2Y(6)R expression level in mouse liver, which was positively correlated with CCL2 mRNA induction. Unexpectedly, the CDAHFD treatment for 6 weeks increased liver weights with severe steatosis in both wild-type (WT) and P2Y(6)R knockout (KO) mice, while the disease marker levels such as serum AST and liver CCL2 mRNA in CDAHFD-treated P2Y(6)R KO mice were rather aggravated compared with those of CDAHFD-treated WT mice. Thus, P2Y(6)R may not contribute to the progression of liver injury, despite increased expression in NASH liver.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] P2Y6 purinergic receptor regulates steroid synthesis and proliferation of ovarian luteal cells
    Bao, Riqiang
    Xu, Ping
    Wang, Yishu
    Li, Jiaheng
    Zhang, Junhao
    Wang, Jing
    Tang, Min
    Zhang, Chunping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (08): : 11508 - 11518
  • [32] Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis
    Pohl, Rebekka
    Feder, Susanne
    Haberl, Elisabeth M.
    Rein-Fischboeck, Lisa
    Weiss, Thomas S.
    Spirk, Marlen
    Bruckmann, Astrid
    McMullen, Nichole
    Sinal, Christopher J.
    Buechler, Christa
    BIOMEDICINES, 2022, 10 (01)
  • [33] Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
    Lebeau, Paul F.
    Byun, Jae Hyun
    Platko, Khrystyna
    Al-Hashimi, Ali A.
    Lhotak, Sarka
    MacDonald, Melissa E.
    Mejia-Benitez, Aurora
    Prat, Annik
    Igdoura, Suleiman A.
    Trigatti, Bernardo
    Maclean, Kenneth N.
    Seidah, Nabil G.
    Austin, Richard C.
    JHEP REPORTS, 2019, 1 (06) : 418 - 428
  • [34] Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non-alcoholic steatohepatitis
    Tiburcio, Tayna Cristina
    Willebrords, Joost
    da Silva, Tereza Cristina
    Alves Pereira, Isabel Veloso
    Nogueira, Marina Sayuri
    Yanguas, Sara Crespo
    Maes, Michael
    Silva, Elisangela dos Anjos
    Zaidan Dagli, Maria Lucia
    de Castro, Inar Alves
    Oliveira, Claudia Pinto
    Vinken, Mathieu
    Cogliati, Bruno
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (02): : 197 - 206
  • [35] Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis
    McKee, Chad
    Soeda, Junpei
    Asilmaz, Esra
    Sigalla, Barbara
    Morgan, Maelle
    Sinelli, Nicoletta
    Roskams, Tania
    Oben, Jude A.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 437 (04) : 597 - 602
  • [36] Participation of P2Y2 and P2Y6 purinergic receptors in the physiopathology of glaucoma.
    Fonseca, Begona
    Martinez-Aguila, Alejandro
    Perez de lara, Maria J.
    Crooke, Almudena
    Pintor, Jesus
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [37] Effect Of A Purinergic P2y6 Receptor Agonist On Airway remodeling And Responsiveness in A Mouse Model Of asthma
    Chetty, A.
    Sharda, A.
    Warburton, R.
    Chen, T.
    Xue, C.
    Castellot, J.
    Haydon, P. G.
    Nielsen, H. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [38] Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease
    Somers, GR
    Hammet, FMA
    Trute, L
    Southey, MC
    Venter, DJ
    LABORATORY INVESTIGATION, 1998, 78 (11) : 1375 - 1383
  • [39] Lack of adipocyte purinergic P2Y6 receptor greatly improves whole body glucose homeostasis
    Jain, Shanu
    Pydi, Sai P.
    Toti, Kiran S.
    Robaye, Bernard
    Idzko, Marco
    Gavrilova, Oksana
    Wess, Jurgen
    Jacobson, Kenneth A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (48) : 30763 - 30774
  • [40] Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation
    Riegel, Ann-Kathrin
    Faigle, Marion
    Zug, Stephanie
    Rosenberger, Peter
    Robaye, Bernard
    Boeynaems, Jean-Marie
    Idzko, Marco
    Eltzschig, Holger K.
    BLOOD, 2011, 117 (08) : 2548 - 2555